Antifungal agents in clinical and preclinical development: overview and analysis
The World Health Organization (WHO) has released its first analysis of antifungal agents in clinical and preclinical development. The report evaluates the current pipeline, including label extension and repurposed products, and its effectiveness in addressing infections caused by WHO fungal priority pathogens. It also highlights financial and technical limitations in antifungal drug development, particularly in low-resource settings.
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Your Biweekly Source for Global AMR Insights!
Stay informed with the essential newsletter that brings together all the latest One Health news on antimicrobial resistance. Delivered straight to your inbox every two weeks, AMR NEWS provides a curated selection of international insights, key publications, and the latest updates in the fight against AMR.
Don’t miss out on staying ahead in the global AMR movement—subscribe now!
